Ig Vena

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as a sterile solution for injection for intravenous use. It provides pooled IgG antibodies to patients with primary or secondary immunodeficiency diseases and to those with immune‑mediated conditions such as idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance for biologic medicines.

Ig Vena (Human Normal Immunoglobulin) is used to replace deficient antibodies in various immunodeficiency and immune‑mediated disorders.

- Primary immunodeficiency diseases: restores IgG levels to reduce infection risk. - Secondary immunodeficiency: provides passive immunity for patients with acquired antibody deficiency. - Idiopathic thrombocytopenic purpura: raises platelet counts by modulating auto‑immune activity. - Kawasaki disease: reduces coronary artery inflammation and fever in acute cases. - Chronic inflammatory demyelinating polyneuropathy: improves nerve conduction by attenuating autoimmune attack.

Ig Vena may be associated with a range of adverse reactions, most of which are infusion‑related.

Common Side Effects: - Headache: mild to moderate pain during or after infusion. - Fever and chills: transient rise in body temperature. - Nausea or vomiting: gastrointestinal discomfort. - Fatigue or malaise: feeling of tiredness post‑infusion. - Mild infusion reactions: flushing, itching, or low blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation in veins or arteries. - Acute renal failure: sudden loss of kidney function. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells. - Severe thrombocytopenia: marked drop in platelet count.

Prior to initiating Ig Vena therapy, clinicians should evaluate patient‑specific risk factors and monitor during treatment. - Renal function: assess baseline renal status and monitor creatinine during therapy. - Thrombotic risk: review history of thrombosis and consider prophylactic measures. - Infusion rate: start at a low rate and increase gradually to minimize reactions. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - IgA deficiency: monitor closely for anaphylaxis in patients with anti‑IgA antibodies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with other agents that affect immune function or hemostasis.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy and increase infection risk. - C1 esterase inhibitor deficiency: heightened risk of angioedema. - High‑dose aspirin or anticoagulants: increased bleeding tendency.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., corticosteroids, azathioprine): monitor infection signs. - Diuretics: watch for fluid shifts and electrolyte imbalance. - ACE inhibitors: observe for hypotension during infusion.